HC Wainwright Reiterates Buy Rating for Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $90.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 67.38% […]
22 Sep 08:40 · The Markets Daily